glp 1 pills lilly Eli to seek approval of new GLP-1 weight-loss drug this year FDA approves new weight-loss pill,
Description
Risk of Retained Gastric Contents in Patients Using GLP-1RAs or Tirzepatide Presenting for Endoscopy or General Anesthesia Retrospective studies suggest that individuals on GLP-1-based therapy (exenatide, liraglutide, dulaglutide, semaglutide, or tirzepatide) appear to be at an increased risk of having retained gastric contents [Supplementary Table S3 (21)
Novo Nordisk Foundation, Denmark), EliteForsk Rejsestipendiat (2016), The Danish Council for Independent Research (DFF 1333-00206A), the Danish Diabetes Academy (PhD funding), the Augustinus Foundation 140962, Aase og Ejnar Danielsens Fond, Mrsk Fonden, Holger Rabitz fond, Lge Johannes Nicolaj Krogsgaard og hustru Else Krogsgaards minde-legat for medicinsk forskning og medicinske studenter ved Kbenhavns Universitet, the European Molecular Biology Organization and the European Foundation for the Study of Diabetes
In the real world, it generally involves using doses lower than the established therapeutic amount needed to achieve the intended medical benefit
For that, for this part of the story
Standardised questionnaires are used, administered to the patient and/or their healthcare provider
